Literature DB >> 26717321

Natural Nuclear Factor Kappa Beta Inhibitors: Safe Therapeutic Options for Inflammatory Bowel Disease.

Murtaza M Tambuwala1.   

Abstract

Inflammatory bowel disease (IBD) is a chronic and debilitating condition classified as ulcerative colitis and Crohn's disease. IBD usually happens as result of immune dysfunction in the intestinal mucosa resulting in epithelial barrier dysfunction, which leads to exposure of the mucosal immune system to luminal antigenic material. This results in activation of inflammation, which is our bodies natural defense system; however, chronic inflammation leads to barrier dysfunction, which triggers a cycle of inflammation and further barrier dysfunction. This barrier breakdown results in the uncontrolled progression of IBD throughout the intestine. Despite the therapeutic advances made over the last decade, the current first line of treatment of IBD is limited to immunosuppressive and anti-inflammatory drugs, which need to be taken regularly and have significant side effects to the patients. Prolonged inflammation may increase the risk of intestinal malignancy. The role of nuclear factor kappa beta (NF-κβ) has been established in the regulation of innate immunity and inflammation. NF-κβ has also shown to be involved in critical events linking inflammation and cancer development. Recent investigations suggest that the NF-κβ signaling cascade may be the central mediator of gastrointestinal inflammation in IBD and malignancies including esophageal, gastric, and colorectal cancers. In this review, the therapeutic potential of natural NF-κβ inhibitors as safe therapeutic options for the treatment of IBD will be discussed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26717321     DOI: 10.1097/MIB.0000000000000655

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  6 in total

1.  An engineered cyclic peptide alleviates symptoms of inflammation in a murine model of inflammatory bowel disease.

Authors:  Claudia Cobos Caceres; Paramjit S Bansal; Severine Navarro; David Wilson; Laurianne Don; Paul Giacomin; Alex Loukas; Norelle L Daly
Journal:  J Biol Chem       Date:  2017-05-04       Impact factor: 5.157

Review 2.  Zinc and Selenium in Inflammatory Bowel Disease: Trace Elements with Key Roles?

Authors:  Mostafa Vaghari-Tabari; Davoud Jafari-Gharabaghlou; Fatemeh Sadeghsoltani; Parisa Hassanpour; Durdi Qujeq; Nadereh Rashtchizadeh; Amir Ghorbanihaghjo
Journal:  Biol Trace Elem Res       Date:  2020-10-23       Impact factor: 3.738

3.  Caffeic acid phenethyl ester is protective in experimental ulcerative colitis via reduction in levels of pro-inflammatory mediators and enhancement of epithelial barrier function.

Authors:  Mohammed N Khan; Majella E Lane; Paul A McCarron; Murtaza M Tambuwala
Journal:  Inflammopharmacology       Date:  2017-05-20       Impact factor: 4.473

4.  Deficiency of miRNA-149-3p shaped gut microbiota and enhanced dextran sulfate sodium-induced colitis.

Authors:  Qingqing Feng; Yuanqiang Li; Hongli Zhang; Ziwei Wang; Xiaobo Nie; Denglin Yao; Lu Han; Wei-Dong Chen; Yan-Dong Wang
Journal:  Mol Ther Nucleic Acids       Date:  2022-09-24       Impact factor: 10.183

5.  Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α.

Authors:  Alaa A A Aljabali; Hamid A Bakshi; Faruk L Hakkim; Yusuf A Haggag; Khalid M Al-Batanyeh; Mazhar S Al Zoubi; Bahaa Al-Trad; Mohamed M Nasef; Saurabh Satija; Meenu Mehta; Kavita Pabreja; Vijay Mishra; Mohammed Khan; Salem Abobaker; Ibrahim M Azzouz; Harish Dureja; Ritesh M Pabari; Ashref Ali K Dardouri; Prashant Kesharwani; Gaurav Gupta; Shakti Dhar Shukla; Parteek Prasher; Nitin B Charbe; Poonam Negi; Deepak N Kapoor; Dinesh Kumar Chellappan; Mateus Webba da Silva; Paul Thompson; Kamal Dua; Paul McCarron; Murtaza M Tambuwala
Journal:  Cancers (Basel)       Date:  2020-01-01       Impact factor: 6.639

6.  Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial.

Authors:  Ryan Bradley; Blake O Langley; Jennifer J Ryan; John Phipps; Douglas A Hanes; Emily Stack; Janet K Jansson; Thomas O Metz; Jan Frederik Stevens
Journal:  Trials       Date:  2020-10-07       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.